What are the long-term effects of Ryeqo (unknown medication) on bone density?

From the Guidelines

Ryeqo's long-term effects on bone density are unknown, and therefore, its use should be approached with caution, prioritizing established treatments for osteoporosis or low bone mass that have a proven track record of reducing fracture risk, as recommended by the American College of Physicians 1.

Key Considerations

• The American College of Physicians recommends pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women with known osteoporosis, based on high-quality evidence 1.
• For men with clinically recognized osteoporosis, bisphosphonates are recommended to reduce the risk for vertebral fracture, although this is based on low-quality evidence 1.
• The decision to treat osteopenic women 65 years of age or older who are at high risk for fracture should be based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications, as suggested by the American College of Physicians 1.

Bone Health Maintenance

• Adequate calcium and vitamin D intake should be part of fracture prevention in all adults with low bone mass or osteoporosis, as emphasized in the living clinical guideline from the American College of Physicians 1.
• Clinicians should encourage adherence to recommended treatments and healthy lifestyle modifications, including exercise, and counseling for evaluation and prevention of falls 1.

Treatment Duration and Monitoring

• The duration of bisphosphonate therapy should be limited to 3 to 5 years unless there is a strong indication for treatment continuation, due to the increased risk for long-term harms 1.
• Regular bone density monitoring during the treatment period is not recommended for most patients, according to the American College of Physicians 1.

From the Research

Long-term Effects of Ryeqo on Bone Density

There are no research papers to assist in answering this question, as Ryeqo is not mentioned in any of the provided studies.

Available Information on Osteoporosis Treatment

• The treatment of osteoporosis mainly includes antiresorptives (i.e. estrogens, selective estrogen receptor modulators, bisphosphonates, denosumab) and anabolic agents (i.e. teriparatide, abaloparatide, romosozumab) 2.
• Bisphosphonates and denosumab are antiresorptives that target the osteoclast and inhibit bone resorption, with denosumab achieving greater suppression of bone turnover and greater increases of bone mineral density (BMD) at all skeletal sites 3.
• Bisphosphonates are generally considered safe and are the first choice for the treatment of osteoporosis, with some bisphosphonates providing 7% to 8% increases in bone mineral density and 60% to 70% decreases in markers of bone resorption 4.
• Denosumab is an alternative to bisphosphonates and may be given as initial therapy to select patients, with a favorable safety profile and efficacy in decreasing fracture risk 5.
• Combination therapy of anabolic and anti-resorptive agents is expected to be an ideal anti-osteoporosis option, with natural compounds such as phytoestrogens, antioxidant and anti-inflammatory agents, and treatments that exert their effects by multiple actions providing a safer alternative to primary pharmacological strategies 6.